Growth Equity

Transit-tech firm Argo gets a $1.4M boost from TheVentureCity, a fund led by a former Facebook colleague of Argo's CEO, to scale its smart city solutions.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

Commodity giant Mercuria secures copper and gold from Pucobre's El Espino mine with a $375M financing deal, betting big on Chile and green metals.

Facing soaring demand, AI robotics firm TechForce is seeking a global manufacturing partner, signaling a major shift from pilot programs to mass production.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

New data reveals a stark split in private markets. Capital floods into infrastructure and AI, while concerns over PE exits and real estate persist.

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Varsity Healthcare Partners' new foundation applies investment-grade rigor to its giving, funding charities with measurable health and wellness impacts.

A massive USD 300M investment in a Quebec copper foil plant is set to eliminate a critical EV battery vulnerability for North America. Here's why.

A C$1M private placement for CHAR Technologies signals strong investor faith in its waste-to-energy tech, promising to decarbonize heavy industry.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

Streamex's $12.2M stake in Empress Royalty isn't just a purchase; it's a blueprint for tokenizing real-world assets and reshaping commodity markets.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

With Sir Nick Clegg and AI pioneer Yann LeCun on board, HIRO Capital's new fund is a bold bet on Europe's ability to lead in deep tech innovation.

A Hong Kong award for Youxin Technology offers a deeper look into the firm's strategic acquisition, its role in the GBA, and what it means for investors.

A modest SEK 1.5 million order may not turn heads, but for Cell Impact, it's a critical validation that could unlock mass production in the booming Asian FCEV market.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.